NO20055724L - Immunogene humane TNF alfa analoger med redusert cytotoksisiter og fremgangsmater for deres fremstilling - Google Patents

Immunogene humane TNF alfa analoger med redusert cytotoksisiter og fremgangsmater for deres fremstilling

Info

Publication number
NO20055724L
NO20055724L NO20055724A NO20055724A NO20055724L NO 20055724 L NO20055724 L NO 20055724L NO 20055724 A NO20055724 A NO 20055724A NO 20055724 A NO20055724 A NO 20055724A NO 20055724 L NO20055724 L NO 20055724L
Authority
NO
Norway
Prior art keywords
tnfα
analog
preparation
methods
tnf alpha
Prior art date
Application number
NO20055724A
Other languages
English (en)
Inventor
Steen Klysner
Soren Mouritsen
Finn Stausholm Nielsen
Tomas Bratt
Bjorn Voldborg
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of NO20055724L publication Critical patent/NO20055724L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Foreliggende oppfinnelse fremskaffer en immonogenisk analog av human TNFa protein, hvor nevnte analog omfatter et immunogenisert monomert TNFa polypeptid eller TNFa di- eller trimer, og hvor analogen ytterhgere omfatter toksisitetsreduserende eller -fjernende mutasjoner valgt blant gruppen bestående av Y87S, D 143N eller A145R, hvor aminosyrenummereringen er fra den N-terminale valin i humant TNFa. Oppfinnelsen fremskaffer også nukleinsyrefragment som koder for analogen så vel som vektorer og transformerte celler som er nyttige i fremstillingen av analogen. Det blir også diskutert fremgangsmåter for nedregulering av TNFa i et individ med behov for dette.
NO20055724A 2003-05-09 2005-11-30 Immunogene humane TNF alfa analoger med redusert cytotoksisiter og fremgangsmater for deres fremstilling NO20055724L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46949103P 2003-05-09 2003-05-09
DKPA200300701 2003-05-09
PCT/DK2004/000329 WO2004099244A2 (en) 2003-05-09 2004-05-06 Immunogenic human tnf alpha analogues with reduced cytotoxicity and methods of their preparation

Publications (1)

Publication Number Publication Date
NO20055724L true NO20055724L (no) 2005-11-30

Family

ID=33436006

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055724A NO20055724L (no) 2003-05-09 2005-11-30 Immunogene humane TNF alfa analoger med redusert cytotoksisiter og fremgangsmater for deres fremstilling

Country Status (11)

Country Link
US (1) US20060222624A1 (no)
EP (1) EP1625157A2 (no)
JP (1) JP2007523605A (no)
KR (1) KR20060015595A (no)
AU (1) AU2004235875A1 (no)
CA (1) CA2524623A1 (no)
EA (1) EA008254B1 (no)
MX (1) MXPA05011965A (no)
NO (1) NO20055724L (no)
NZ (1) NZ543976A (no)
WO (1) WO2004099244A2 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1054937A (en) 1975-01-28 1979-05-22 Gursaran P. Talwar Antipregnancy vaccine
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
AU5993186A (en) 1985-06-04 1987-01-07 Biotechnology Research Partners Limited Autoantigen vaccines
JPH02177896A (ja) * 1988-12-28 1990-07-10 Teijin Ltd 新規生理活性ポリペプチド
CN1615316A (zh) * 2001-11-16 2005-05-11 法麦克萨有限公司 多聚体蛋白质的新免疫原性模拟物
US20030185845A1 (en) * 2001-11-16 2003-10-02 Steen Klysner Novel immunogenic mimetics of multimer proteins

Also Published As

Publication number Publication date
EA200501773A1 (ru) 2006-06-30
JP2007523605A (ja) 2007-08-23
CA2524623A1 (en) 2004-11-18
EP1625157A2 (en) 2006-02-15
KR20060015595A (ko) 2006-02-17
AU2004235875A1 (en) 2004-11-18
US20060222624A1 (en) 2006-10-05
WO2004099244A3 (en) 2004-12-29
WO2004099244A2 (en) 2004-11-18
EA008254B1 (ru) 2007-04-27
NZ543976A (en) 2008-04-30
MXPA05011965A (es) 2006-02-02

Similar Documents

Publication Publication Date Title
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
DK1317537T3 (da) Sammensætninger og fremgangsmåder med G-CSF analoger
DK1844150T3 (da) Rekombinant ekspression af proteiner i en to-kædet form med disulfidbroer
RU2001117230A (ru) Пептиды, ингибирующие трансформирующий фактор роста tgf$$$1
ATE417595T1 (de) Keratin-bindende polypeptide
NO20011861L (no) Interferon-<beta> fusjonsproteiner samt anvendelse derav
ATE540111T1 (de) Hla-dr-bindendes antigenpeptid, das von wt1 abgeleitet ist
BR0107703A (pt) Flavivìrus recombinantes e processos para uso dos mesmos
CN101257917A (zh) 针对黄病毒科病毒感染的嵌合多肽及其治疗应用
Xia et al. Cloning and expression of interferon-α/γ from a domestic porcine breed and its effect on classical swine fever virus
NO20052807L (no) Fremgangsmate for fremstilling av aminosyrer
BRPI0411363A (pt) seqüências de ácidos nucléicos codificando e composições compreendendo peptìdeo sinal ige e/ou il-15 e processos para uso das mesmas
WO2021198706A3 (en) Coronavirus vaccines
DK0479912T3 (da) Fremgangsmåde til hæmning af N-endereglens forløb i levende celler
BR112022011975A2 (pt) Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo
DK0851926T3 (da) Varianter af humant rekombinant gamminterferon (rhu-IFN-gamma) med forøget termisk stabilitet
NO20055724L (no) Immunogene humane TNF alfa analoger med redusert cytotoksisiter og fremgangsmater for deres fremstilling
Jarpe et al. Predicted structural motif of IFNτ
DE602004027362D1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
DE60323634D1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
ES2044881T3 (es) Procedimiento para la preparacion de una fosfoproteina estructural (pp 150) del citomegalovirus humano.
DK1305334T3 (da) Urocortinproteiner og anvendelser deraf
ES2290156T3 (es) Vector de expresion y secrecion del alfa interferon humano y procedimiento para producir alfa interferon humano empleando el anterior.
DE69935599D1 (de) Modifizierte hcv peptid-impfstoffe
Cao et al. Characterization, cloning and expression of the 67-kDA annexin from chicken growth plate cartilage matrix vesicles

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application